Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 11, 2011

Novartis Discontinues a Phase III Study in Gastrointestinal Stromal Tumors

  • Novartis is discontinuing the Phase III Enestg1 study evaluating Tasigna® (nilotinib) as first-line therapy for gastrointestinal stromal tumors (GIST). The study’s independent data monitoring committee said interim data from the trial suggest it is unlikely to demonstrate any benefits of Tasigna over Glivec® (imatinib) in terms of improving progression-free survival. The Enestg1 trial was initiated in 2009, and aimed to enroll over 700 GIST patients newly diagnosed with unresectable and/or metastatic GIST.

    Tasigna is already approved in major markets including the EU, U.S,. and Japan, for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

    The drug has also been approved in over 90 countries for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients who are resistant or intolerant to at least one prior therapy, including Glivec.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »